Codexis (CDXS) Competitors $2.43 -0.01 (-0.41%) Closing price 04:00 PM EasternExtended Trading$2.43 0.00 (0.00%) As of 06:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CDXS vs. ZBIO, RIGL, VSTM, MYGN, XOMA, EBS, LXRX, CBIO, VNDA, and IRWDShould you be buying Codexis stock or one of its competitors? The main competitors of Codexis include Zenas BioPharma (ZBIO), Rigel Pharmaceuticals (RIGL), Verastem (VSTM), Myriad Genetics (MYGN), XOMA Royalty (XOMA), Emergent Biosolutions (EBS), Lexicon Pharmaceuticals (LXRX), Crescent Biopharma (CBIO), Vanda Pharmaceuticals (VNDA), and Ironwood Pharmaceuticals (IRWD). These companies are all part of the "biotechnology" industry. Codexis vs. Its Competitors Zenas BioPharma Rigel Pharmaceuticals Verastem Myriad Genetics XOMA Royalty Emergent Biosolutions Lexicon Pharmaceuticals Crescent Biopharma Vanda Pharmaceuticals Ironwood Pharmaceuticals Codexis (NASDAQ:CDXS) and Zenas BioPharma (NASDAQ:ZBIO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, media sentiment, analyst recommendations, earnings, institutional ownership and dividends. Does the media refer more to CDXS or ZBIO? In the previous week, Zenas BioPharma had 3 more articles in the media than Codexis. MarketBeat recorded 6 mentions for Zenas BioPharma and 3 mentions for Codexis. Codexis' average media sentiment score of 1.19 beat Zenas BioPharma's score of 0.18 indicating that Codexis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Codexis 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zenas BioPharma 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher valuation & earnings, CDXS or ZBIO? Codexis has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Codexis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCodexis$59.35M3.70-$65.28M-$0.83-2.93Zenas BioPharma$15M56.79-$156.99M-$3.55-5.70 Do institutionals & insiders hold more shares of CDXS or ZBIO? 78.5% of Codexis shares are owned by institutional investors. 1.9% of Codexis shares are owned by company insiders. Comparatively, 16.5% of Zenas BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Do analysts prefer CDXS or ZBIO? Codexis currently has a consensus target price of $11.00, suggesting a potential upside of 352.67%. Zenas BioPharma has a consensus target price of $36.67, suggesting a potential upside of 81.25%. Given Codexis' higher possible upside, equities research analysts clearly believe Codexis is more favorable than Zenas BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Codexis 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Zenas BioPharma 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is CDXS or ZBIO more profitable? Zenas BioPharma has a net margin of 0.00% compared to Codexis' net margin of -113.67%. Zenas BioPharma's return on equity of -59.21% beat Codexis' return on equity.Company Net Margins Return on Equity Return on Assets Codexis-113.67% -105.83% -46.06% Zenas BioPharma N/A -59.21%-50.56% SummaryCodexis beats Zenas BioPharma on 8 of the 15 factors compared between the two stocks. Get Codexis News Delivered to You Automatically Sign up to receive the latest news and ratings for CDXS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CDXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CDXS vs. The Competition Export to ExcelMetricCodexisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$219.36M$3.12B$5.79B$10.15BDividend YieldN/A2.32%5.69%4.61%P/E Ratio-2.9321.3074.5925.92Price / Sales3.70240.30449.5483.33Price / CashN/A45.3337.0859.91Price / Book2.969.6112.156.29Net Income-$65.28M-$53.29M$3.28B$270.85M7 Day Performance0.41%0.29%0.98%3.36%1 Month Performance-15.03%8.91%7.20%6.41%1 Year Performance-10.99%13.14%63.06%28.26% Codexis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CDXSCodexis3.3955 of 5 stars$2.43-0.4%$11.00+352.7%-10.6%$219.36M$59.35M-2.93250Positive NewsZBIOZenas BioPharma0.976 of 5 stars$21.51+4.9%$36.67+70.5%N/A$863.68M$5M-6.06N/AHigh Trading VolumeRIGLRigel Pharmaceuticals2.0524 of 5 stars$40.87-1.1%$38.20-6.5%+191.6%$741.53M$179.28M7.55160News CoveragePositive NewsShort Interest ↓VSTMVerastem2.7361 of 5 stars$10.23-5.0%$13.29+29.9%+233.9%$662.84M$2.14M-3.1250News CoveragePositive NewsAnalyst ForecastMYGNMyriad Genetics3.7207 of 5 stars$6.91+4.5%$12.45+80.2%-70.8%$615.03M$832.90M-1.612,700Positive NewsXOMAXOMA Royalty4.2085 of 5 stars$35.35+0.3%$69.50+96.6%+39.1%$425.97M$28.49M-22.8110Positive NewsAnalyst UpgradeEBSEmergent Biosolutions4.7471 of 5 stars$7.59+0.1%$14.33+88.9%+8.6%$404.40M$812.50M3.102,420LXRXLexicon Pharmaceuticals2.1941 of 5 stars$1.08-0.9%$3.23+198.6%-34.3%$396.11M$31.08M-3.27140CBIOCrescent Biopharma4.3954 of 5 stars$12.95-9.1%$25.60+97.7%N/A$278.39M$10K-0.3750VNDAVanda Pharmaceuticals4.1812 of 5 stars$4.55-1.3%$16.50+262.6%-6.5%$272.40M$198.77M-4.03290Positive NewsIRWDIronwood Pharmaceuticals4.2426 of 5 stars$1.13-2.2%$4.94+337.2%-71.5%$187.61M$351.41M-22.60220News CoveragePositive NewsAnalyst Revision Related Companies and Tools Related Companies ZBIO Alternatives RIGL Alternatives VSTM Alternatives MYGN Alternatives XOMA Alternatives EBS Alternatives LXRX Alternatives CBIO Alternatives VNDA Alternatives IRWD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CDXS) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredWall Street laughed at Trump’s “Smart Dollar.” Now they’re all in."THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Codexis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Codexis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
